[{"id":"bfbf8c75-c7b7-4a8c-ab2c-a6d960bd0ab5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03557359","created_at":"2021-07-05T17:14:56.675Z","updated_at":"2025-02-25T14:27:06.322Z","phase":"Phase 2","brief_title":"Nivolumab for Recurrent or Progressive IDH Mutant Gliomas","source_id_and_acronym":"NCT03557359","lead_sponsor":"Fabio Iwamoto, MD","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-18"},{"id":"f3d782d2-7f3d-4ad2-b8d5-99602c17c34a","acronym":"SONOBIRD","url":"https://clinicaltrials.gov/study/NCT05902169","created_at":"2023-06-13T17:08:12.284Z","updated_at":"2024-07-02T16:34:26.706Z","phase":"Phase 3","brief_title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","source_id_and_acronym":"NCT05902169 - SONOBIRD","lead_sponsor":"CarThera","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • IDH1 R132H • IDH1 R132","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • lomustine"],"overall_status":"Recruiting","enrollment":" Enrollment 560","initiation":"Initiation: 01/29/2024","start_date":" 01/29/2024","primary_txt":" Primary completion: 01/28/2028","primary_completion_date":" 01/28/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-06-12"},{"id":"450196e9-e0ad-47bf-a736-4b3fdabb7b6e","acronym":"NCI-2019-03057","url":"https://clinicaltrials.gov/study/NCT03953898","created_at":"2021-01-18T19:27:50.729Z","updated_at":"2024-07-02T16:34:37.850Z","phase":"Phase 2","brief_title":"Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation","source_id_and_acronym":"NCT03953898 - NCI-2019-03057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-06"},{"id":"8420d34e-5720-4abb-8b0f-9d930a4e3baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03212274","created_at":"2021-01-18T15:50:38.215Z","updated_at":"2024-07-02T16:35:02.706Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT03212274","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-17"},{"id":"6fd39586-a5ba-42d4-9b04-4797a9ca665f","acronym":"GESTALT","url":"https://clinicaltrials.gov/study/NCT05342883","created_at":"2022-04-25T22:54:38.331Z","updated_at":"2024-07-02T16:35:03.480Z","phase":"Phase 4","brief_title":"GammaTile and Stupp in Newly Diagnosed GBM","source_id_and_acronym":"NCT05342883 - GESTALT","lead_sponsor":"GT Medical Technologies, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132H • IDH wild-type • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH wild-type • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-15"},{"id":"caba8d6b-3a99-4cf4-a5f0-d1c3cfbe3575","acronym":"","url":"https://clinicaltrials.gov/study/NCT03343197","created_at":"2021-01-18T16:30:40.675Z","updated_at":"2024-07-02T16:35:17.668Z","phase":"Phase 1","brief_title":"Study of AG-120 and AG-881 in Subjects With Low Grade Glioma","source_id_and_acronym":"NCT03343197","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" ATRX mutation • IDH1 R132H • IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Voranigo (vorasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 08/02/2019","primary_completion_date":" 08/02/2019","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-02-26"},{"id":"f25cf478-f7d0-48ec-a823-1e8a5b6955d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04764474","created_at":"2022-03-09T14:53:09.433Z","updated_at":"2024-07-02T16:35:19.376Z","phase":"Phase 1","brief_title":"A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH","source_id_and_acronym":"NCT04764474","lead_sponsor":"Hutchmed","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ranosidenib (HMPL-306)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 02/28/2021","start_date":" 02/28/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-02-14"},{"id":"d6d10093-3f56-4d6a-b230-8bbd9e5b7bfd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03687957","created_at":"2021-12-02T23:53:46.042Z","updated_at":"2024-07-02T16:35:23.583Z","phase":"Phase 1/2","brief_title":"rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide","source_id_and_acronym":"NCT03687957","lead_sponsor":"Washington University School of Medicine","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" IDH1 R132H • IDH wild-type • IDH1 R132","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH wild-type • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Hyleukin-7 (efineptakin alfa)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 01/31/2032","primary_completion_date":" 01/31/2032","study_txt":" Completion: 01/31/2032","study_completion_date":" 01/31/2032","last_update_posted":"2024-01-12"},{"id":"bd470247-33b7-45c3-a313-a7729d609e0e","acronym":"NRG-BN011","url":"https://clinicaltrials.gov/study/NCT05095376","created_at":"2021-10-27T15:53:22.431Z","updated_at":"2024-07-02T16:35:23.915Z","phase":"Phase 3","brief_title":"Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma","source_id_and_acronym":"NCT05095376 - NRG-BN011","lead_sponsor":"NRG Oncology","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH1 R132H • IDH1 R132","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine"],"overall_status":"Recruiting","enrollment":" Enrollment 306","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 08/08/2026","primary_completion_date":" 08/08/2026","study_txt":" Completion: 08/08/2031","study_completion_date":" 08/08/2031","last_update_posted":"2024-01-10"},{"id":"77149011-4b82-46a9-addd-cd3261cdd6a7","acronym":"INDIGO","url":"https://clinicaltrials.gov/study/NCT04164901","created_at":"2021-01-18T20:19:25.505Z","updated_at":"2024-07-02T16:35:27.123Z","phase":"Phase 3","brief_title":"Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)","source_id_and_acronym":"NCT04164901 - INDIGO","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 01/05/2020","start_date":" 01/05/2020","primary_txt":" Primary completion: 09/06/2022","primary_completion_date":" 09/06/2022","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2023-12-05"},{"id":"4332101d-7ce0-4281-baf4-5b9d31806fda","acronym":"","url":"https://clinicaltrials.gov/study/NCT05303519","created_at":"2022-03-31T17:52:38.349Z","updated_at":"2024-07-02T16:35:29.269Z","phase":"Phase 2","brief_title":"Safusidenib Phase 2 Study in IDH1 Mutant Glioma","source_id_and_acronym":"NCT05303519","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132C • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132C • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3295668 • safusidenib (DS-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2023-11-14"},{"id":"c80eeae2-933f-4349-b377-8932b9e3ffc9","acronym":"rQNestin","url":"https://clinicaltrials.gov/study/NCT03152318","created_at":"2022-10-22T19:05:45.181Z","updated_at":"2024-07-02T16:35:40.606Z","phase":"Phase 1","brief_title":"A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2","source_id_and_acronym":"NCT03152318 - rQNestin","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • linoserpaturev (CAN-3110)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 07/18/2017","start_date":" 07/18/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-08"},{"id":"2325ad67-a6c7-40b4-b0a4-40263229ded9","acronym":"RIGOLETTO","url":"https://clinicaltrials.gov/study/NCT04933942","created_at":"2021-06-22T15:52:35.716Z","updated_at":"2024-07-02T16:35:47.227Z","phase":"Phase 2","brief_title":"Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma","source_id_and_acronym":"NCT04933942 - RIGOLETTO","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH1 R132H • IDH1 R132","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • Nplate (romiplostim)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 12/19/2022","primary_completion_date":" 12/19/2022","study_txt":" Completion: 12/19/2022","study_completion_date":" 12/19/2022","last_update_posted":"2023-05-24"},{"id":"52a9e97d-ec8c-4452-bd98-75d58884d9a5","acronym":"THERABIOME-GBM","url":"https://clinicaltrials.gov/study/NCT05326334","created_at":"2022-04-13T11:55:12.234Z","updated_at":"2024-07-02T16:35:50.496Z","phase":"","brief_title":"THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)","source_id_and_acronym":"NCT05326334 - THERABIOME-GBM","lead_sponsor":"Ottawa Hospital Research Institute","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132H","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2023-04-17"},{"id":"09433bad-7c17-41a7-b1ca-4ac19bbc5a86","acronym":"STEAM","url":"https://clinicaltrials.gov/study/NCT03224104","created_at":"2021-01-18T15:54:47.667Z","updated_at":"2024-07-02T16:36:09.663Z","phase":"Phase 1","brief_title":"Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma","source_id_and_acronym":"NCT03224104 - STEAM","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" IDH1 • IDH2 • MCL1 • CDK9","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132","tags":["IDH1 • IDH2 • MCL1 • CDK9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • zotiraciclib (TG02)"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 05/05/2022","primary_completion_date":" 05/05/2022","study_txt":" Completion: 05/05/2022","study_completion_date":" 05/05/2022","last_update_posted":"2022-05-31"},{"id":"fd121c3c-52f5-4798-a112-02173c47c64f","acronym":"OLAGLI","url":"https://clinicaltrials.gov/study/NCT03561870","created_at":"2021-01-18T17:31:47.568Z","updated_at":"2024-07-02T16:36:11.208Z","phase":"Phase 2","brief_title":"Olaparib in Recurrent IDH-mutant Glioma","source_id_and_acronym":"NCT03561870 - OLAGLI","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • IDH1 R132H • IDH1 R132","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 11/08/2021","primary_completion_date":" 11/08/2021","study_txt":" Completion: 11/24/2021","study_completion_date":" 11/24/2021","last_update_posted":"2022-04-29"},{"id":"82f2ff91-c9b2-437a-91b0-1a704c957940","acronym":"NOA-16","url":"https://clinicaltrials.gov/study/NCT02454634","created_at":"2021-01-18T11:46:29.017Z","updated_at":"2024-07-02T16:37:05.534Z","phase":"Phase 1","brief_title":"Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas","source_id_and_acronym":"NCT02454634 - NOA-16","lead_sponsor":"National Center for Tumor Diseases, Heidelberg","biomarkers":" IDH1 • IFNG • ATRX","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132","tags":["IDH1 • IFNG • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1R132H peptide vaccine"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 09/19/2017","primary_completion_date":" 09/19/2017","study_txt":" Completion: 09/19/2017","study_completion_date":" 09/19/2017","last_update_posted":"2018-11-07"}]